trending Market Intelligence /marketintelligence/en/news-insights/trending/ocFKN18Q7rxk-tYw8Qt-8Q2 content esgSubNav
In This List

Moody's deems court ruling on Restasis credit negative for Allergan

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Moody's deems court ruling on Restasis credit negative for Allergan

Moody's said the Texas district court ruling to invalidate Allergan plc's patents on its dry eye drug Restasis is credit negative for the company.

The U.S. District Court for the Eastern District of Texas ruled that four U.S. patents protecting Restasis until 2024 were invalid. The ruling could allow the companies to market a generic version of the drug, Reuters reported.

Moody's added that there was no impact on the Baa3 ratings on rated subsidiaries including Allergan Inc. and Allergan Funding SCS, or on the stable rating outlook.